We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Novel SLN Tracer Maps Breast Cancer Metastasis

By MedImaging International staff writers
Posted on 01 Sep 2016
A new study describes how a novel sentinel lymph node (SLN) radiotracer helps determine breast cancer spread by targeting a specific antigen.

Researchers at Beijing Cancer Hospital (BJC; Beijing, China) and Peking University Cancer Hospital & Institute (Beijing, China) conducted a retrospective study of 2,317 patients with primary breast cancer who underwent lymphoscintigraphy and sentinel lymph node biopsy (SLNB). Before imaging, all patients were administered a preoperative peritumoral injection of 37 MBq of 99mTc-rituximab, a new SLN radiotracer that binds to the antigen CD20, which is expressed extensively in lymph nodes.

Image: A sentinel node biopsy for breast cancer diagnosis (Photo courtesy of CancerQuest).
Image: A sentinel node biopsy for breast cancer diagnosis (Photo courtesy of CancerQuest).

Initial results in 100 randomly selected patients showed that the detection rate for SLN by injection of Tc-99m-rituximab, as verified by lymphoscintigraphy, was 100%. SLNs from the 100 patients were then harvested, guided by a hand-held gamma-detecting probe, and biopsied with a similar success rate of 100%. When examining results of the other 2,217 patients in the study, the detection rate was 98.8% percent for lymphoscintigraphy and 99.9 % for SLN biopsy. The study was published in the August 2016 issue of The Journal of Nuclear Medicine.

“The advantage of Tc-99m-rituximab is its uniform molecular weight and molecular size. It does not escape easily from SLNs to the second echelon lymph nodes,” said senior author Zhi Yang, PhD, chair of the department of nuclear medicine at BJC. “This results in clear SLN imaging in patients and the high success rate of lymphoscintigraphy. In addition, technical factors, such as the injection dose, injection volume and injection site, can be well controlled.”

Lymph nodes serve as biologic filters that contain immune cells to fight infection and clean the blood. When cancer cells break away from a tumor, they can travel through the lymph system; sentinel node surgery allows the surgeon to remove the nodes to determine cancer spread. Since human lymph nodes are only a half-centimeter in size, they are difficult to discern among the surrounding tissue during surgery. Furthermore, even when surgeons are able to map the location of the nodes, there is no current technique that indicates whether or not the lymph nodes contain cancer, requiring removal of more lymph nodes than necessary.

Related Links:
Beijing Cancer Hospital


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Brachytherapy Planning System
Oncentra Brachy
Ultrasound Doppler System
Doppler BT-200
PACS Workstation
CHILI Web Viewer

Latest Radiography News

Novel Breast Imaging System Proves As Effective As Mammography

AI Assistance Improves Breast-Cancer Screening by Reducing False Positives

AI Could Boost Clinical Adoption of Chest DDR